The Antiresorptive Effect of GIP, But Not GLP‐2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study

Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐2 (GLP‐2) are gut hormones secreted postprandially. In healthy humans, both hormones decrease bone resorption accompanied by a rapid reduction in parathyroid hormone (PTH). The aim of this study was to investigate whether the changes in bone turnover after meal intake and after GIP‐ and GLP‐2 injections, respectively, are mediated via a reduction in PTH secretion. This was tested in female patients with hypoparathyroidism given a standardized liquid mixed‐meal test (n = 7) followed by a peptide injection test (n = 4) using a randomized crossover design. We observed that the meal‐ and GIP‐ but not the GLP‐2‐induced changes in bone turnover markers were preserved in the patients with hypoparathyroidism. To understand the underlying mechanisms, we examined the expression of the GIP receptor (GIPR) and the GLP‐2 receptor (GLP‐2R) in human osteoblasts and osteoclasts as well as in parathyroid tissue. The GIPR was expressed in both human osteoclasts and osteoblasts, whereas the GLP‐2R was absent or only weakly expressed in osteoclasts. Furthermore, both GIPR and GLP‐2R were expressed in parathyroid tissue. Our findings suggest that the GIP‐induced effect on bone turnover may be mediated directly via GIPR expressed in osteoblasts and osteoclasts and that this may occur independent of PTH. In contrast, the effect of GLP‐2 on bone turnover seems to depend on changes in PTH and may be mediated through GLP‐2R in the parathyroid gland. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

[1]  J. Holst,et al.  GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. , 2020, The Journal of clinical endocrinology and metabolism.

[2]  J. Holst,et al.  Consumption of nutrients and insulin resistance suppress markers of bone turnover in subjects with abdominal obesity. , 2020, Bone.

[3]  M. Rosenkilde,et al.  Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long‐term impairment of the GIP system , 2019, Basic & clinical pharmacology & toxicology.

[4]  J. Holst,et al.  GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. , 2019, Bone.

[5]  J. Holst,et al.  Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. , 2019, The Journal of clinical endocrinology and metabolism.

[6]  J. Holst,et al.  Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment , 2019, Front. Endocrinol..

[7]  H. Johnsen,et al.  TAFA2 Induces Skeletal (Stromal) Stem Cell Migration Through Activation of Rac1‐p38 Signaling , 2018, Stem cells.

[8]  Michael C. Ostrowski,et al.  Enhancer variants reveal a conserved transcription factor network governed by PU.1 during osteoclast differentiation , 2018, Bone Research.

[9]  S. Khosla,et al.  Legumain Regulates Differentiation Fate of Human Bone Marrow Stromal Cells and Is Altered in Postmenopausal Osteoporosis , 2017, Stem cell reports.

[10]  M. Rubin,et al.  Bone imaging in hypoparathyroidism , 2017, Osteoporosis International.

[11]  A. Tura,et al.  Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[12]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[13]  L. Rejnmark,et al.  Postsurgical Hypoparathyroidism—Risk of Fractures, Psychiatric Diseases, Cancer, Cataract, and Infections , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  M. Christensen,et al.  Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. , 2014, The Journal of clinical endocrinology and metabolism.

[15]  B. Clarke.  Bone disease in hypoparathyroidism. , 2014, Arquivos brasileiros de endocrinologia e metabologia.

[16]  G. González,et al.  Feeding and bone turnover in gastric bypass. , 2014, The Journal of clinical endocrinology and metabolism.

[17]  T. Hansen,et al.  A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. , 2014, The Journal of clinical endocrinology and metabolism.

[18]  B. Hartmann,et al.  Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure , 2013, Regulatory Peptides.

[19]  W. Fraser,et al.  Receptors and effects of gut hormones in three osteoblastic cell lines , 2011, BMC Physiology.

[20]  H. Karga,et al.  Effect of an Oral Glucose Load on PTH, 250HD3, Calcium, and Phosphorus Homeostasis in Postmenopausal Women , 2011, Endocrine research.

[21]  J. Delaissé,et al.  Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[23]  M. Rubin,et al.  Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. , 2010, Arquivos brasileiros de endocrinologia e metabologia.

[24]  Matthew D. Young,et al.  Gene ontology analysis for RNA-seq: accounting for selection bias , 2010, Genome Biology.

[25]  J. Holst,et al.  Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. , 2009, Bone.

[26]  J. Holst,et al.  Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract , 2008, Scandinavian journal of gastroenterology.

[27]  J. Holst,et al.  Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome , 2008, Scandinavian journal of gastroenterology.

[28]  J. Holst,et al.  Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. , 2007, Bone.

[29]  W. Bollag,et al.  Effects of glucose-dependent insulinotropic peptide on osteoclast function. , 2007, American journal of physiology. Endocrinology and metabolism.

[30]  DIMITRIOS J. HADJIDAKIS,et al.  Bone Remodeling , 2006, Annals of the New York Academy of Sciences.

[31]  T. Plesner,et al.  Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. , 2005, Cancer research.

[32]  J. Holst,et al.  Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  R. Eastell,et al.  Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. , 2003, The Journal of clinical endocrinology and metabolism.

[34]  J. Holst,et al.  Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. , 2003, The Journal of clinical endocrinology and metabolism.

[35]  R. Eastell,et al.  Acute changes of bone turnover and PTH induced by insulin and glucose: euglycemic and hypoglycemic hyperinsulinemic clamp studies. , 2002, The Journal of clinical endocrinology and metabolism.

[36]  T. Jensen,et al.  Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells , 2002, Nature Biotechnology.

[37]  M. Bjerknes,et al.  Modulation of specific intestinal epithelial progenitors by enteric neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  H. Rasmussen,et al.  Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. , 2000, Endocrinology.

[39]  J. Holst,et al.  GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2. , 2019, Bone.

[40]  J. Holst,et al.  Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia , 2018, The Journal of clinical endocrinology and metabolism.

[41]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[42]  J. Holst,et al.  Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. , 2004, Bone.

[43]  C. Christiansen,et al.  Mechanism of circadian variation in bone resorption. , 2002, Bone.